We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 1,962

U.S. Supreme Court agrees to hear patent case that could impact timing of availability of more affordable multiple sclerosis treatment

  • Heslin Rothenberg Farley & Mesiti PC
  • -
  • USA
  • -
  • April 16 2014

The United States Supreme Court has granted certiorari in a patent case that could extend the market exclusivity of a top-selling multiple sclerosis

Notice of proposed amendment of the Pharmaceutical Affairs Act

  • Yoon & Yang LLC
  • -
  • South Korea
  • -
  • April 16 2014

On March 21, 2014, the Ministry of Food and Drug Safety ("MFDS") released for public consultation the proposed amendment (the "Proposed Amendment"

Venlafaxine section 8 decision follows “roadmap” set out in previous decisions

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 14 2014

In this decision under section 8 of the Patented Medicines (Notice of Compliance) Regulations ("Regulations"), Justice Zinn of the Federal Court

Is there a way to patent stem cells in Europe?

  • FRKelly
  • -
  • European Union
  • -
  • April 14 2014

It's no news that the European Patent Convention (EPC) does not allow European Patents to be granted in respect of biotechnological inventions

Uncertainty remains over medical device SPCs in Europe

  • EIP
  • -
  • European Union
  • -
  • April 10 2014

The UK Intellectual Property Office has refused to grant an SPC for a medical device, as noted in the decision BL O14114. Whilst those aware of the

Novartis AG and Another v Ranbaxy (Malaysia) Sdn. Bhd.

  • Henry Goh & Co Sdn Bhd
  • -
  • Singapore
  • -
  • April 10 2014

In the case of Novartis AG and Another v Ranbaxy (Malaysia) Sdn. Bhd. 2013 2 SLR 117, the plaintiff was the proprietor of a Singapore patent and the

The COPAXONE story in the U.S. and India: a further update

  • Michael Best & Friedrich LLP
  • -
  • India, USA
  • -
  • April 9 2014

As an update to our March 5th and April 4th postings, The Copaxone Story in the U.S. and India and The Copaxone Story in the U.S. and India: An

Ex Parte Martin Gleave: Enablement of method of treatment claims does not require description of all of the method’s “particulars”

  • Perkins Coie LLP
  • -
  • USA
  • -
  • April 8 2014

For some unpredictable fields, like cancer therapeutics, one of skill in the art is able to, and even expects or anticipates the need to, fine-tune

T 222110 - EPO confirms the extent of G 0206

  • D Young & Co
  • -
  • European Union
  • -
  • April 7 2014

Over the past 18 months we have reported on the Court of Justice of the European Union (CJ) decision in Brüstle v Greenpeace (C-3410) which

Bolar exemption - C-66113 - Astellas Pharma referral to the CJ

  • D Young & Co
  • -
  • European Union, Germany
  • -
  • April 7 2014

The Dusseldorf Court of Appeal has referred questions to the Court of Justice of the European Union (CJ) concerning the applicability of the